10:24 AM EST - Aeterna Zentaris Inc. : Today announced its Autoimmunity Modifying Biologicals program has achieved pre-clinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder (also known as “Devic disease”), a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve and spinal cord and which can be fatal in approximately 30% of patients within five years of diagnosis. These findings were presented at the 13th International Congress on Autoimmunity being held June 10-13, in Athens, Greece.
Aeterna Zentaris Inc.
shares T.AEZS are trading unchanged at $0.25.
